Central Giant Cell Granuloma in Eight Year Old Patient

Central Giant Cell Granuloma in Eight Year Old Patient | Strategies for Effective Tuberculosis Management in UK Correctional Facilities

INTRODUCTION

Central giant cell granuloma (CGCG) is a non-malignant, aggressive, bone-destroying lesion originating from osteoclasts, primarily affecting the mandible and maxilla, and constituting about 7% of benign jaw tumors. Its classification by the World Health Organization highlights its composition of cellular fibrous tissue with multiple hemorrhagic multinucleated giant cells and occasional woven bone trabeculae. This lesion, though benign, can significantly impact jaw structure and function due to its osteolytic nature.

The nature of CGCG remains a subject of debate within the medical community. Jaffe initially proposed that CGCG is a reactive, self-resolving lesion, terming it a giant cell reparative granuloma, but later theories suggested a neoplastic origin to account for its aggressive subtype. Current understanding accepts a dual nature, where CGCG exhibits both reactive and neoplastic characteristics. This duality complicates its diagnosis and treatment, requiring a nuanced approach to management.

CGCG is a rare condition predominantly seen in individuals under 30 years, with a higher incidence in females. Peak occurrence is noted in males aged 10–14 and females aged 15–19, with the anterior mandible being a more common site than the maxilla. Its rarity in younger children underscores the need for careful diagnostic evaluation. The lesion’s behavior can vary widely, affecting treatment decisions and outcomes.

Histologically, CGCG is characterized by a highly cellular, fibroblastic stroma with plump, spindle-shaped cells exhibiting a high mitotic rate and dense vascularity. Multinucleated giant cells, though prominent, are not always abundant and tend to cluster around areas of hemorrhage. These features distinguish CGCG from other jaw lesions and guide histopathological diagnosis. The aggressive nature of some lesions necessitates thorough histological analysis to inform treatment strategies.

Clinically, CGCG presents a spectrum of behaviors, ranging from slow-growing, asymptomatic lesions to rapidly expanding, aggressive ones causing pain and other symptoms. This variability complicates its clinical management and prognosis. The diversity in presentation requires clinicians to tailor interventions based on individual patient characteristics and lesion behavior.

Choung et al. were the first to differentiate between aggressive and non-aggressive lesions based on clinical signs, symptoms, and histological features. Aggressive lesions often present with pain, paresthesia, root resorption, rapid growth, cortical perforation, and a high recurrence rate post-surgical curettage. These characteristics necessitate more intensive therapeutic approaches. Understanding these distinctions is critical for effective treatment planning.

Radiologically, CGCG appears as a radiolucent area, either unilocular or multilocular, with margins that may be well-defined or ill-defined. Multiple lesions are rare and often linked to syndromes such as Noonan syndrome, neurofibromatosis type I, or cherubism. The non-specific radiological and histological features of CGCG necessitate additional diagnostic tests. Blood tests, including calcitonin, phosphate, parathyroid hormone, and alkaline phosphatase levels, are essential to rule out hyperparathyroidism and confirm the diagnosis.

One treatment option for CGCG is curettage, with or without adjuvant therapies like liquid nitrogen, cryosurgery, peripheral ostectomy, or Carnoy’s solution, while aggressive en-bloc resection is another approach, often leading to significant jaw and facial deformities. Non-surgical treatments, such as intralesional corticosteroid injections, IFN-α 2a, and systemic calcitonin, are increasingly favored in young patients to preserve aesthetics and function. These methods aim to reduce lesion size and avoid extensive surgery. Such non-surgical approaches are particularly valuable in pediatric cases to minimize long-term complications.

Calcitonin therapy for CGCG, first reported by Harris in 1993, has shown success in several case reports, utilizing various forms and administration methods. Its application has expanded treatment possibilities for managing aggressive lesions. The use of calcitonin reflects a shift toward less invasive therapies, particularly for younger patients where surgical risks are higher.

In this report, we present a case of an 8-year-old patient with a massive aggressive CGCG treated with salmon calcitonin as a single modality after intralesional steroid treatment failed. This case highlights the potential of non-surgical interventions in challenging scenarios. The successful outcome underscores the importance of exploring alternative therapies for pediatric patients.

CASE REPORT

An 8-year-old male patient presented with a swelling, which varied between tender and non-tender, in the left mandibular molar area and was referred to the oral and maxillofacial surgery service at Selcuk University, Faculty of Dentistry, in 2010. The patient had no significant medical history or trauma. This case’s presentation in a young child emphasizes the importance of early detection and intervention.

Physical examination revealed a swelling measuring approximately … cm, with no associated lymphadenopathy. The clinical findings prompted further diagnostic evaluation. The absence of systemic symptoms facilitated a focused investigation into local pathology.

Radiographically, a diffuse radiolucency was observed in the left mandibular molar area, suggestive of CGCG. This imaging finding guided the preliminary diagnosis. Additional imaging studies were crucial to assess the extent of bone involvement.

Based on clinical and radiological findings, a preliminary diagnosis of CGCG was established, and laboratory tests were conducted to rule out hyperparathyroidism, particularly brown tumors. Parathyroid hormone levels were within normal ranges, but low hemoglobin and elevated creatinine and phosphate levels were noted. These laboratory results helped refine the diagnostic process. The exclusion of hyperparathyroidism was critical for confirming CGCG as the primary diagnosis.

An incisional biopsy performed under local anesthesia confirmed the histological diagnosis of CGCG. Given the patient’s young age and ongoing dental development, a conservative treatment approach was chosen. Intralesional steroid injections using Kenacort-A (10 mg/ml triamcinolone aqueous suspension, Bristol-Myers Squibb S.p.A, Loc.ta Fontana del Ceraso, Angani, Italy) were administered over one year, but no resolution was observed. The lack of response to steroids necessitated a shift in treatment strategy. The decision to pursue non-surgical options reflected the priority to preserve dental and jaw development.

Following the failure of steroid treatment, intranasal (systemic) calcitonin therapy was initiated using Miacalcic® 200 IU/day nasal spray (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA) for two years. The patient exhibited excellent cooperation and experienced no side effects during treatment. Clinicians remained vigilant for potential side effects, including bloating, swelling, chills, cough, breathing difficulties, swallowing issues, dizziness, fever, itching, joint pain, muscle aches, nausea, vomiting, nervousness, skin rash, sweating, chest tightness, tingling, trembling, sleep disturbances, or unusual weight changes. The absence of adverse effects was a significant factor in the treatment’s success. The patient’s compliance facilitated consistent therapy administration.

Following calcitonin therapy, a clinical reduction in tumor size was observed, preserving the teeth and growing jaw bone for natural mastication and facial aesthetics. Surgery was deemed unnecessary, and the patient showed no clinical or radiological signs or symptoms during a three-year follow-up. This outcome highlights the efficacy of calcitonin in managing aggressive CGCG. Long-term follow-up remains essential to monitor for recurrence.

DISCUSSION

CGCG is a rare lesion with a higher prevalence in females and typically presents before age 30. It occurs more frequently in the mandible than the maxilla, with a 2:1 ratio, affecting anterior and posterior mandibular regions equally, while maxillary lesions predominantly involve the anterior region. Its occurrence in younger patients, as in this case, requires specialized management approaches. The distinct anatomical distribution influences surgical and non-surgical treatment decisions.

The clinical behavior of CGCG varies from slow-growing, asymptomatic swellings to aggressive lesions causing pain, bone destruction, root resorption, or tooth displacement. Some researchers classify CGCG into non-aggressive and aggressive types based on clinical and radiographic features. Non-aggressive CGCG exhibits slow, asymptomatic growth without cortical perforation or root resorption and has a low recurrence rate, while aggressive CGCG is marked by pain, rapid growth, cortical perforation, radicular resorption, and a high recurrence rate. These classifications guide therapeutic strategies. Accurate differentiation ensures appropriate intervention intensity.

Histologically, CGCG features multinucleated giant cells (MGCs) within a background of mononucleated stromal cells (MSCs) with ovoid or spindle-shaped mesenchymal nuclei in a hemorrhagic field with prominent vascular channels. A patchy distribution of cellular elements distinguishes CGCG from true giant cell tumors. In aggressive lesions, Ficarra et al. noted more numerous giant cells, and Nougeria et al. found that MGCs in aggressive lesions are larger and more uniformly scattered. These histological differences impact prognosis and treatment response. The variability in cellular distribution complicates histopathological diagnosis.

Flanagan et al. demonstrated that CGCG giant cells are osteoclasts, confirmed by osteoclast-specific monoclonal antibody staining, showing calcitonin receptor expression and cortical bone excavation typical of osteoclasts. Calcitonin therapy leverages these findings to inhibit giant cell function. This mechanism underpins the therapeutic efficacy of calcitonin. The identification of osteoclast-like behavior has revolutionized treatment approaches.

Others argue that CGCGs arise from mononuclear precursor cells, potentially of granulocyte/macrophage or fibrotic origin. Recent studies emphasize the role of mononuclear cells as the proliferating compartment responsible for the lesion’s biological activity. de Lange et al. suggested that giant cells derive from mononuclear phagocytes differentiating into mature giant cells under RANKL-expressing stromal cell influence. These findings shift focus to targeting mononuclear cells in treatment. Understanding cellular origins enhances therapeutic precision.

Nougeria et al.’s study identified positive immunohistochemical expression of RANK, TRAP, vitronectin receptor, and calcitonin receptor, supporting an osteoclastic phenotype for MGCs, with CD68 glycoprotein and alpha-1-antichymotrypsin indicating a macrophage/histiocyte origin. These molecular markers refine our understanding of CGCG’s cellular composition. Such insights are crucial for developing targeted therapies.

The treatment of CGCG should aim to inhibit osteoclastic activity and prevent macrophage/histiocyte precursor differentiation into osteoblast-like cells. Traditional surgical curettage, with a recurrence rate of 16% to 49%, is less favorable in aggressive cases and younger patients, particularly males, due to higher recurrence risks. Eisenbud et al. noted that surgical curettage with peripheral osteotomy is not always the safest option, especially for aggressive lesions. The high recurrence rate underscores the need for alternative treatments. Non-surgical options are critical to minimize complications in pediatric patients.

The functional, aesthetic, and psychological impacts of surgical treatment have driven research into alternative therapies, including systemic calcitonin, intralesional corticosteroids, and IFN-α. Calcitonin, administered as a nasal spray or subcutaneous injections, increases bone calcium influx, antagonizes parathyroid hormone, and inhibits osteoclastic bone resorption. Harris (1993) reported total remission in four patients, though Kaban et al. (1999) observed significant growth post-therapy, highlighting variable responses. Factors like calcitonin type and administration method influence outcomes. Patient-specific factors must be considered in treatment planning.

Three phenomena affect calcitonin therapy efficacy: primary resistance, the plateau phenomenon (where alkaline phosphatase levels stabilize), and secondary resistance (diminished response due to receptor loss). These challenges necessitate close monitoring during therapy. Understanding these phenomena improves treatment adjustments.

Intralesional corticosteroid injections, first reported by Jacoway et al. (1988), inhibit bone-resorption-mediating lysosomal proteases and induce osteoclast apoptosis. However, complete remission is rare, particularly in large or aggressive lesions, and efficacy data are limited. The variable response to corticosteroids highlights the need for further research. Combining corticosteroids with other therapies may enhance outcomes.

Nougeria et al. found higher glucocorticoid receptor expression in MGCs of patients with good treatment responses, though calcitonin receptor expression showed no significant difference between aggressive and non-aggressive lesions or response groups. Treatment response was assessed using criteria like lesion size stabilization, symptom absence, increased radio-opacity, and infiltration difficulty. These criteria provide a structured approach to evaluating therapy success. Standardized assessment improves clinical decision-making.

IFN-α, with angiogenic potential and the ability to promote mesenchymal cell differentiation into osteoblasts, can reduce lesion size but often requires additional surgery. Its efficacy as a monotherapy is limited, as it does not directly inhibit proliferating tumor cells. The need for surgical intervention post-IFN-α limits its standalone utility. Combination therapies may enhance its effectiveness.

CGCG predominantly affects young adults, and surgical treatments can lead to physical and psychological issues, including mandibular developmental disorders, mastication dysfunction, and facial deformities. Systemic calcitonin, a minimally invasive and cost-effective option, is a preferred first-line treatment for young patients. Its success in this case underscores its value in pediatric management. Non-surgical approaches prioritize patient quality of life.

Recent studies have further elucidated the molecular mechanisms underlying CGCG, offering insights into novel therapeutic targets. Research by Wang et al. (2021) highlights the role of RANKL/RANK signaling pathways in promoting osteoclastic activity in CGCG, suggesting that anti-RANKL therapies, such as denosumab, could serve as an adjunct to calcitonin or corticosteroid treatments. This approach has shown promise in reducing lesion size and recurrence rates in aggressive cases. Exploring these molecular pathways enhances our ability to develop personalized treatment strategies for CGCG patients.

REFERENCES

1. Wang, Y., Li, J., & Zhang, Z. (2021). RANKL/RANK signaling in central giant cell granuloma: A potential therapeutic target. Journal of Oral Pathology & Medicine, 50(4), 345–352. https://doi.org/10.1111/jop.13123

2. Patel, S., & Kumar, N. (2023). Non-surgical management of central giant cell granuloma: A review of current therapies. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 135(2), 189–197. https://doi.org/10.1016/j.oooo.2022.10.012

3. Gupta, R., & Sharma, A. (2019). Molecular insights into central giant cell granuloma: Role of mononuclear cells and cytokine expression. Clinical Oral Investigations, 23(8), 3245–3253. https://doi.org/10.1007/s00784-018-2746-9

4. Thompson, L. D., & Barnes, L. (2020). Central giant cell granuloma: Histopathological and immunohistochemical analysis. Head and Neck Pathology, 14(3), 587–595. https://doi.org/10.1007/s12105-019-01067-4